Redeye comments on Hansa Biopharma's Q3 report. Product sales declined sequentially in Europe.
Redeye was surprised by the news that CEO Johan Rask is leaving the company.
Net sales from continuing operations was 4% below our expectation in Q3.
Administer is set to report Q3 results on November 5.
Marimekko’s Q3 brought no major surprises, with both net sales and profitability roughly in line wit...
Redeye initiates coverage of Boreo, an emerging serial acquirer primarily focusing on Finland and th...
Redeye updates its estimates and valuation following Tradedoubler’s Q3 2025 report.
Redeye updates its forecast and valuation following Modelon’s Q3 2025 report, which was broadly in l...
* EBIT to increase by 58% y-o-y to SEK 30m in Q3'25e * Minor negative tweaks to our 2025e EBIT * 202...
Finnair’s biggest challenges this year may now be in the past, yet it still needs to achieve signifi...
YIT’s Q3 results overall corresponded to expectations but was positive in terms of profitability of ...
Oriola posted good Q3 results, with a key positive the faster recovery than we had expected recovery...
With the admission to the London Stock Exchange Main Market, at Friday, 31st October, and the prospe...
Redeye provides an initial comment on Tradedoubler’s Q3 2025 report.
* Continued gross margin expansion, but the market remains tough * We take a more cautious view on t...
